Astrazeneca Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
AstraZeneca Pharma's recent management commentary and industry dynamics suggest a stable outlook for the company, despite moderating revenue growth. The management's focus on innovative therapies and biosimilars aligns with the broader industry trend of improving pricing power and expanding market opportunities. This strategic emphasis is crucial as it positions AstraZeneca to capitalize on the growing demand for chronic therapies, particularly in the Indian market. Vista's financial outlook reflects a conservative revenue growth forecast, supported by stable profit margins and a conservatively financed balance sheet. The company's low leverage enhances its financial stability, allowing for continued investment in R&D and product development. While the macroeconomic environment in India remains favorable, with contained inflation and strong liquidity, potential headwinds from rising input costs and currency fluctuations could impact margins. Over the next 12-24 months, AstraZeneca's ability to navigate these challenges while leveraging its innovative pipeline will be critical. The company is well-positioned to maintain its competitive position, but investors should monitor the evolving market dynamics and regulatory landscape closely
Why We Like This Stock
Things To Watch Out For
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,296 | 1,716 | 2,276 | 2,437 | 2,756 |
| Profit Before Tax (Cr.) | 204 | 252 | 257 | 219 | 264 |
| PBT Margin | 15.7% | 14.7% | 1129.2% | 9.0% | 9.6% |
| Net Profit (Cr.) | 370 | 331 | 192 | 162 | 195 |
| Earnings Per Share | 148.1 | 132.5 | 76.8 | 64.8 | 78.0 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.